Related Experiment Video

Updated: Jul 12, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs

Charles Swanton1, Barbara Nicke, Michela Marani

  • 1Signal Transduction Laboratory, Cancer Research UK London Research Institute, London, UK. charles.swanton@cancer.org.uk

Cell Cycle (Georgetown, Tex.)
|August 28, 2007
PubMed

Insights

Drug resistance to non cross-resistant chemotherapy agents in advanced solid tumors is a challenge. Kinase activity significantly influences this multi-drug resistance, varying by tumor type.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Standard cancer treatment involves sequential non cross-resistant chemotherapy to improve survival and quality of life.
  • Drug resistance to these agents is common in advanced solid tumors, leading to declining treatment efficacy.
  • The molecular basis for resistance to non cross-resistant agents remains unclear, with ABC transporters offering incomplete explanations.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying resistance to non cross-resistant chemotherapy agents.
  • To identify specific kinases involved in multi-drug resistance across different cancer types.
  • To explore potential therapeutic targets for overcoming chemotherapy resistance.

Main Methods:

  • Statistical analysis of a large-scale RNA interference (RNAi) screen targeting 779 kinases.
  • Utilized three distinct cell lines representing different tumor types.
  • Assessed correlations between kinase expression and resistance to paclitaxel and a non cross-resistant agent.

Main Results:

  • A significant correlation was found between resistance to paclitaxel and a non cross-resistant agent, mediated by specific kinases.
  • Approximately 20% of kinases conferring paclitaxel resistance also conferred resistance to the non cross-resistant agent within the same cell line, indicating tissue-type dependence.
  • Kinases specific to paclitaxel resistance or sensitization were less frequent than anticipated.

Conclusions:

  • Cell line-specific kinases play a crucial role in regulating multi-drug resistance.
  • These findings offer a potential molecular explanation for observed clinical resistance to non cross-resistant agents in oncology.
  • Identified common and specific kinase pathways involved in drug response, supporting future drug discovery efforts.

More Related Videos

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence10:09

Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence

Published on: January 7, 2019

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...